Business Context and Reporting Period
Lipocine Inc. filed this Form 8-K on November 12, 2015, to disclose a Regulation FD event. The company is a biopharmaceutical firm focused on developing oral testosterone products.
Key Financial Metrics
This filing is a current report regarding a clinical study presentation and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
No material financial changes versus prior periods are reported in this filing. The primary event is the scheduled presentation of clinical data.
Outlook, Management Commentary, and Risks
- Clinical Study Update: The company will present data from its pivotal Phase 3 clinical study, known as the Study of Oral Androgen Replacement ("SOAR"), evaluating the efficacy and safety of LPCN 1021.
- Target Population: The study focuses on hypogonadal men with low testosterone ("Low T").
- Event Details: Presentations will occur at the 21st Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Las Vegas, NV.
- Exhibits: Posters and abstracts for the SMSNA meeting are attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific efficacy and safety results of the SOAR Phase 3 study once the SMSNA presentation materials are released.
- Confirm the regulatory implications of the LPCN 1021 data for future FDA approval.
- Review the attached Exhibit 99.1 for detailed abstracts and poster content.